[Retracted] The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance

Table 3

Logistic regression analysis of clinical characteristics of sPD-L1 and SCLC patients.

Variable	Univariate logistic analysis			Multivariate logistic analysis
	OR	95% CI	value	OR	95% CI	value
Female	0.62	0.27~0.81	0.35	0.51	0.22~1.02	0.13
Age (per 1 year increase)	1.056	0.75~1.05	0.76	1.04	0.93~1.07	0.57
Tumor staging
Phase I	2.08	0.88~8.03	0.54	1.37	0.89~1.62	0.58
Phase II	1.06	0.47~2.45	0.04	1.22	0.30~4.83	0.47
Phase III	1.53	0.82~3.66	0.08	1.70	0.64~5.08	0.32
Smoking history (years)	2.56	1.30~6.06	0.01	2.74	0.9I~7.04	0.04
Lung cancer brain metastasis (case)	1.95	0.97~0.99	0.01	1.27	0.94~0.98	0.01
Lung cancer liver metastasis (case)	1.05	0.81~0.99	0.63	0.97	0.84~1.12	0.44
ProGRP (per 1 ng/mL increase)	2.04	1.84~3.99	0.01	1.50	1.04~2.86	0.01